Merck & Co., Inc. (MRK) Position Increased by Willingdon Wealth Management

Willingdon Wealth Management boosted its position in shares of Merck & Co., Inc. (NYSE:MRK) by 3.2% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 35,973 shares of the company’s stock after purchasing an additional 1,113 shares during the quarter. Willingdon Wealth Management’s holdings in Merck & Co., Inc. were worth $2,024,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in MRK. Martingale Asset Management L P boosted its holdings in shares of Merck & Co., Inc. by 6.3% during the 2nd quarter. Martingale Asset Management L P now owns 735,229 shares of the company’s stock valued at $47,122,000 after acquiring an additional 43,718 shares during the last quarter. Vantage Investment Advisors LLC boosted its holdings in shares of Merck & Co., Inc. by 31.1% during the 2nd quarter. Vantage Investment Advisors LLC now owns 87,203 shares of the company’s stock valued at $5,589,000 after acquiring an additional 20,706 shares during the last quarter. Jackson Wealth Management LLC boosted its holdings in shares of Merck & Co., Inc. by 9.8% during the 2nd quarter. Jackson Wealth Management LLC now owns 57,127 shares of the company’s stock valued at $3,652,000 after acquiring an additional 5,107 shares during the last quarter. CORDA Investment Management LLC. boosted its holdings in shares of Merck & Co., Inc. by 0.3% during the 2nd quarter. CORDA Investment Management LLC. now owns 229,512 shares of the company’s stock valued at $14,709,000 after acquiring an additional 620 shares during the last quarter. Finally, Financial Counselors Inc. boosted its holdings in shares of Merck & Co., Inc. by 1.2% during the 2nd quarter. Financial Counselors Inc. now owns 362,755 shares of the company’s stock valued at $23,249,000 after acquiring an additional 4,476 shares during the last quarter. 74.63% of the stock is currently owned by institutional investors.

How to Become a New Pot Stock Millionaire

In other Merck & Co., Inc. news, insider Weir Mirian M. Graddick sold 60,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $61.63, for a total transaction of $3,697,800.00. Following the sale, the insider now owns 101,484 shares in the company, valued at approximately $6,254,458.92. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Wendell P. Weeks sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $53.57, for a total transaction of $267,850.00. Following the sale, the director now owns 5,100 shares in the company, valued at approximately $273,207. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 82,500 shares of company stock worth $5,026,025. 0.25% of the stock is owned by company insiders.

A number of brokerages have recently issued reports on MRK. Jefferies Group set a $55.00 price target on shares of Merck & Co., Inc. and gave the company a “hold” rating in a report on Friday, March 23rd. ValuEngine cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. DZ Bank upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Tuesday, February 13th. Morgan Stanley increased their price objective on shares of Merck & Co., Inc. from $60.00 to $63.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 7th. Finally, Credit Suisse Group lowered their price objective on shares of Merck & Co., Inc. from $67.00 to $66.00 and set an “outperform” rating on the stock in a research note on Monday, February 5th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $66.47.

NYSE MRK opened at $53.36 on Monday. Merck & Co., Inc. has a 12 month low of $52.83 and a 12 month high of $66.41. The company has a market cap of $143,868.70, a price-to-earnings ratio of 13.41, a PEG ratio of 2.25 and a beta of 0.78. The company has a current ratio of 1.33, a quick ratio of 1.06 and a debt-to-equity ratio of 0.62.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Friday, February 2nd. The company reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.94 by $0.04. Merck & Co., Inc. had a net margin of 6.40% and a return on equity of 28.61%. The company had revenue of $10.43 billion for the quarter, compared to analysts’ expectations of $10.48 billion. During the same quarter last year, the business earned $0.89 EPS. The firm’s revenue was up 3.1% compared to the same quarter last year. analysts expect that Merck & Co., Inc. will post 4.16 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Friday, April 6th. Shareholders of record on Thursday, March 15th were paid a dividend of $0.48 per share. This represents a $1.92 dividend on an annualized basis and a yield of 3.60%. The ex-dividend date of this dividend was Wednesday, March 14th. Merck & Co., Inc.’s payout ratio is 48.24%.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3342899/merck-co-inc-mrk-position-increased-by-willingdon-wealth-management.html.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Laboratory Corp. of America  Set to Announce Quarterly Earnings on Wednesday
Laboratory Corp. of America Set to Announce Quarterly Earnings on Wednesday
$590.45 Million in Sales Expected for Murphy Oil  This Quarter
$590.45 Million in Sales Expected for Murphy Oil This Quarter
Echo Global Logistics  to Release Earnings on Tuesday
Echo Global Logistics to Release Earnings on Tuesday
Texas Pacific Land Trust  to Release Earnings on Wednesday
Texas Pacific Land Trust to Release Earnings on Wednesday
Reata Pharmaceuticals  Raised to “Sell” at BidaskClub
Reata Pharmaceuticals Raised to “Sell” at BidaskClub
Territorial Bancorp  Stock Rating Lowered by BidaskClub
Territorial Bancorp Stock Rating Lowered by BidaskClub


Leave a Reply

© 2006-2018 Ticker Report. Google+.